Technical Data
Hyperforin DCHA ((1R,5R,6R,7S)-2-Hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-enyl)-6-(4-methylpent-3-enyl)-5-(2-methylpropanoyl)bicyclonon-2-ene-4,9-dione . DCHA)
Biochemicals Storage: 4C/-20CShipping: Blue Ice
Key constituent of St. John's wort. Shows properties of potential pharmacological interest, including anti-bacterial, anti-malarial, anti-inflammatory, anti-cancer and anti-angiogenic effects. Anti-depressant and anxiolytic compound. Specific activator of TRPC6 channels. Inhibits the re-uptake of neurotransmitters in synapses (serotonin, norepinephrine, dopamine, GABA, glutamate). Activator of the pregnane X receptor (PXR). Regulates expression of the cytochrome P450 CYP3A4 and CYP2C9 and hepatic drugs metabolism. Potential anti-Alzheimer compound. Potent SIRT1 (sirtuin 1) and SIRT2 (sirtuin 2) inhibitor.

Storage and Stability:
Short-term Storage: +4C
Long-term Storage: -20C
Stable for at least 2 years after receipt when stored at -20C.

CAS Number:

Molecular Formula:
C35H51O4 . C12H24N

Molecular Weight:
Purity: >97% (HPLC)

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
Antibacterial activity of hyperforin from St John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria: C.M. Schempp, et al.; Lancet 353, 2129 (1999)
St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor: L.B. Moore, et al.; PNAS 97, 7500 (2000)
Hyperforin-antidepressant activity by a novel mechanism of action: W.E. Mller, et al.; Pharmacopsychiatry 34 (Suppl 1), S98 (2001)
Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology: P.J. Nathan; J. Psychopharmacol. 15, 47 (2001) (Review)
Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis: C.M. Schempp, et al.; Oncogene 21, 1242 (2002)
Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort: M.L. Buchholzer, et al.; J. Pharmacol. Exp. Ther. 301, 714 (2002)
Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase: D. Albert, et al.; Biochem. Pharmacol. 64, 1767 (2002)
Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures: B.J. Komoroski; Drug Metab. Dispos. 32, 512 (2004)
NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort: V. Kumar, et al.; J. Pharmacol. Sci. 102, 47 (2006)
Hyperforin, a new lead compound against the progression of cancer and leukemia? C. Quiney, et al.; Leukemia 20, 1519 (2006)
Hyperforin-a key constituent of St. John's wort specifically activates TRPC6 channels: K. Leuner, et al.; FASEB J. 21, 4101 (2007)
Phloroglucinol derivatives guttiferone G, aristoforin, and hyperforin: inhibitors of human sirtuins SIRT1 and SIRT2: C. Gey, et al.; Angew. Chem. Int. Ed. Engl. 46, 5219 (2007)
In vitro antimalarial activity of hyperforin, a prenylated acylphloroglucinol. A structure-activity study: L. Verotta, et al.; Bioorg. Med. Chem. Lett. 17, 1544 (2007)
Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo: C. Feisst, et al.; Cell. Mol. Life Sci. 66, 2759 (2009)
Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy: T.N. Griffith, et al.; Curr. Med. Chem. 17, 391 (2010)

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.